EMA批准对Mounjaro的标签更新, 显示它在治疗肥胖病人睡眠性脑膜炎方面的功效。 EMA approves label updates for Mounjaro, showing its efficacy in treating sleep apnea in obese patients.

欧洲药物管理局 (EMA) 已批准更新Eli Lilly的Mounjaro标签,包括治疗肥胖患者阻塞性睡眠呼吸暂停 (OSA) 的好处,而不需要单独批准. The European Medicines Agency (EMA) has approved updates to Eli Lilly's Mounjaro label to include benefits for treating obstructive sleep apnea (OSA) in obese patients, without requiring separate approval. 试验显示,药物将呼吸不规范减少高达63%。 Trials showed the drug reduced breathing irregularities by up to 63%. 这种发展可以增强莉莉在肥胖药物市场上的竞争优势。 This development could enhance Lilly's competitive edge in the obesity drug market. EMA将在保健专业人员的产品信息中添加相关数据。 The EMA will add relevant data to the product information for healthcare professionals.